Department of Pharmacology, School of Medicine, University of California, Irvine, California, USA.
J Pharmacol Exp Ther. 2011 Mar;336(3):908-15. doi: 10.1124/jpet.110.176255. Epub 2010 Dec 15.
α5 Subunit-containing GABA(A) receptors (GABA(A)Rs) and α7 neuronal nicotinic-acetylcholine receptors (nAChRs) are members of the Cys-loop family of ligand-gated ion channels (LGICs) that mediate cognitive and attentional processes in the hippocampus. α5 GABA(A)Rs alter network activity by tonic inhibition of CA1/CA3 pyramidal cells of the hippocampus. Postsynaptic α7 nAChRs in the hippocampus regulate inhibitory GABAergic interneuron activity required for synchronization of pyramidal neurons in the CA1, whereas presynaptic α7 nAChRs regulate glutamate release. Can simultaneous allosteric modulation of these LGICs produce synergistic effects on cognition? We show that combined transient application of two allosteric modulators that individually 1) inhibit α5 GABA(A)Rs and 2) enhance α7 nAChRs causes long-term potentiation (LTP) of mossy fiber stimulation-induced excitatory postsynaptic currents (EPSC) from CA1 pyramidal neurons of rat hippocampal slices. The LTP effect evoked by two compounds is replicated by 3-(2,5-difluorophenyl)-6-(N-ethylindol-5-yl)-1,2,4-triazolo[4,3-b]pyridazine (522-054), a compound we designed to simultaneously inhibit α5 GABA(A)Rs and enhance α7 nAChRs. Selective antagonists for either receptor block sustained EPSC potentiation produced by 522-054. In vivo, 522-054 enhances performance in the radial arm maze and facilitates attentional states in the five-choice serial reaction time trial with similar receptor antagonist sensitivity. These observations may translate into therapeutic utility of dual action compounds in diseases of hippocampal-based cognitive impairment.
α5 亚单位包含的 GABA(A) 受体 (GABA(A)Rs) 和 α7 神经元烟碱型乙酰胆碱受体 (nAChRs) 是配体门控离子通道 (LGICs) 的 Cys 环家族成员,在海马体中介导认知和注意力过程。α5 GABA(A)Rs 通过对海马体 CA1/CA3 锥体神经元的紧张性抑制来改变网络活动。海马体中的突触后 α7 nAChRs 调节抑制性 GABA 能中间神经元的活动,这是 CA1 锥体神经元同步所必需的,而突触前 α7 nAChRs 调节谷氨酸释放。这些 LGIC 的同时变构调节是否会产生协同作用对认知产生影响?我们表明,两种变构调节剂的短暂联合应用,个体地 1)抑制 α5 GABA(A)Rs 和 2)增强 α7 nAChRs,会导致大鼠海马切片 CA1 锥体神经元中由苔藓纤维刺激诱导的兴奋性突触后电流 (EPSC) 的长时程增强 (LTP)。两种化合物引起的 LTP 效应可由我们设计的同时抑制 α5 GABA(A)Rs 和增强 α7 nAChRs 的化合物 3-(2,5-二氟苯基)-6-(N-乙基吲哚-5-基)-1,2,4-三唑并[4,3-b]吡啶 (522-054) 复制。这两种化合物的选择性拮抗剂均可阻断 522-054 产生的持续 EPSC 增强。在体内,522-054 可增强放射臂迷宫中的表现,并在五选择连续反应时间试验中促进注意力状态,其受体拮抗剂敏感性相似。这些观察结果可能转化为基于海马体认知障碍疾病的双重作用化合物的治疗用途。